These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 37686138)

  • 21. Natural History of Non-Alcoholic Fatty Liver Disease: A Study With Paired Liver Biopsies.
    Reddy YK; Marella HK; Jiang Y; Ganguli S; Snell P; Podila PSB; Maliakkal B; Satapathy SK
    J Clin Exp Hepatol; 2020; 10(3):245-254. PubMed ID: 32405181
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Subclinical steatohepatitis and advanced liver fibrosis in health examinees with nonalcoholic fatty liver disease (NAFLD) in 10 South Korean cities: A retrospective cross-sectional study.
    Nah EH; Cho S; Park H; Noh D; Kwon E; Cho HI
    PLoS One; 2021; 16(11):e0260477. PubMed ID: 34818372
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; McNeil R; Turner MJ; Han B; Provenzale D; Choi SS; Moylan CA; Hunt CM
    Aliment Pharmacol Ther; 2018 Jan; 47(2):268-278. PubMed ID: 29115682
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Features of nonalcoholic steatohepatitis in severely obese children and adolescents undergoing sleeve gastrectomy.
    Alqahtani A; Elahmedi M; Alswat K; Arafah M; Fagih M; Lee J
    Surg Obes Relat Dis; 2017 Sep; 13(9):1599-1609. PubMed ID: 28600116
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dyslipidemia as a risk factor for liver fibrosis progression in a multicentric population with non-alcoholic steatohepatitis.
    Méndez-Sánchez N; Cerda-Reyes E; Higuera-de-la-Tijera F; Salas-García AK; Cabrera-Palma S; Cabrera-Álvarez G; Cortez-Hernández C; Pérez-Arredondo LA; Purón-González E; Coronado-Alejandro E; Panduro A; Rodríguez-Hernández H; Cruz-Ramón VC; Valencia-Rodríguez A; Qi X; Hamdan-Pérez N; Aguilar-Olivos NE; Barranco-Fragoso B; Ramírez-Pérez O; Vera-Barajas A
    F1000Res; 2020; 9():56. PubMed ID: 32595949
    [No Abstract]   [Full Text] [Related]  

  • 26. Association between circulating bile acid alterations and nonalcoholic steatohepatitis independent of obesity and diabetes mellitus.
    Jung Y; Koo BK; Jang SY; Kim D; Lee H; Lee DH; Joo SK; Jung YJ; Park JH; Yoo T; Choi M; Lee MK; Kang SW; Chang MS; Kim W; Hwang GS;
    Liver Int; 2021 Dec; 41(12):2892-2902. PubMed ID: 34358397
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The pathologic relevance of metabolic criteria in patients with biopsy-proven nonalcoholic fatty liver disease and metabolic dysfunction associated fatty liver disease: A multicenter cross-sectional study in China.
    Yang RX; Zou ZS; Zhong BH; Deng H; He FP; Shi JP; Zhao CY; Mi YQ; Zhou YJ; Di FS; Zheng RD; Du Q; Shang J; Popovic B; Chen J; Fan JG
    Hepatobiliary Pancreat Dis Int; 2021 Oct; 20(5):426-432. PubMed ID: 34246549
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association Between Quantity of Liver Fat and Cardiovascular Risk in Patients With Nonalcoholic Fatty Liver Disease Independent of Nonalcoholic Steatohepatitis.
    Arulanandan A; Ang B; Bettencourt R; Hooker J; Behling C; Lin GY; Valasek MA; Ix JH; Schnabl B; Sirlin CB; Loomba R
    Clin Gastroenterol Hepatol; 2015 Aug; 13(8):1513-20.e1. PubMed ID: 25661453
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trajectories of Liver Fibrosis and Gene Expression Profiles in Nonalcoholic Fatty Liver Disease Associated With Diabetes.
    Sako S; Takeshita Y; Takayama H; Goto H; Nakano Y; Ando H; Tsujiguchi H; Yamashita T; Arai K; Kaneko S; Nakamura H; Harada K; Honda M; Takamura T
    Diabetes; 2023 Sep; 72(9):1297-1306. PubMed ID: 37343270
    [TBL] [Abstract][Full Text] [Related]  

  • 30. C-peptide is associated with NAFLD inflammatory and fibrotic progression in type 2 diabetes.
    Wang N; Wang Y; Zhang W; Chen Y; Chen X; Wang C; Li Q; Chen C; Jiang B; Lu Y
    Diabetes Metab Res Rev; 2020 Feb; 36(2):e3210. PubMed ID: 31351021
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinicopathological Profile and Outcome of a Large Cohort of Patients with Nonalcoholic Fatty Liver Disease from South Asia: Interim Results of the Indian Consortium on Nonalcoholic Fatty Liver Disease.
    Duseja A; Singh SP; Mehta M; Shalimar ; Venkataraman J; Mehta V; Devadas K; Kar SK; Goyal O; Nagral A; Saigal S; Nijhawan S; Praharaj D; Shukla A; Sharma B; Narayanasamy K; Kumar P; Rao PN; Arora A; Mehta R; Asati P; Ranjan P; Koshy A; Alam S; Mukewar S; Mukewar S; Mohan Prasad VG; Rastogi M; Sanyal AJ
    Metab Syndr Relat Disord; 2022 Apr; 20(3):166-173. PubMed ID: 35085026
    [No Abstract]   [Full Text] [Related]  

  • 32. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies.
    Singh S; Allen AM; Wang Z; Prokop LJ; Murad MH; Loomba R
    Clin Gastroenterol Hepatol; 2015 Apr; 13(4):643-54.e1-9; quiz e39-40. PubMed ID: 24768810
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients.
    Ong JP; Elariny H; Collantes R; Younoszai A; Chandhoke V; Reines HD; Goodman Z; Younossi ZM
    Obes Surg; 2005 Mar; 15(3):310-5. PubMed ID: 15826462
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Severity of metabolic syndrome is greater among nonalcoholic adults with elevated ALT and advanced fibrosis.
    DeBoer MD; Lin B; Filipp SL; Cusi K; Gurka MJ
    Nutr Res; 2021 Apr; 88():34-43. PubMed ID: 33743323
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes.
    Bril F; McPhaul MJ; Caulfield MP; Clark VC; Soldevilla-Pico C; Firpi-Morell RJ; Lai J; Shiffman D; Rowland CM; Cusi K
    Diabetes Care; 2020 Feb; 43(2):290-297. PubMed ID: 31604692
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the chilean population.
    Arab JP; Hernández-Rocha C; Morales C; Vargas JI; Solís N; Pizarro M; Robles C; Sandoval D; Ponthus S; Benítez C; Barrera F; Soza A; Riquelme A; Arrese M
    Gastroenterol Hepatol; 2017; 40(6):388-394. PubMed ID: 28359548
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The roles of type 2 diabetes and obesity in disease activity and progression of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis.
    Shinde S; Nelson DR; Mitroi J; Heaton PC; Hincapie AL; Brouwers B
    Curr Med Res Opin; 2024 Jan; 40(1):59-68. PubMed ID: 37933187
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The triglycerides and glucose (TyG) index: A new marker associated with nonalcoholic steatohepatitis (NASH) in obese patients.
    Rivière B; Jaussent A; Macioce V; Faure S; Builles N; Lefebvre P; Géraud P; Picot MC; Rebuffat S; Renard E; Paradis V; Servais MD; de Preville N; Nocca D; Lajoix AD; Pageaux GP; Galtier F;
    Diabetes Metab; 2022 Jul; 48(4):101345. PubMed ID: 35339664
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In Children With Nonalcoholic Fatty Liver Disease, Zone 1 Steatosis Is Associated With Advanced Fibrosis.
    Africa JA; Behling CA; Brunt EM; Zhang N; Luo Y; Wells A; Hou J; Belt PH; Kohil R; Lavine JE; Molleston JP; Newton KP; Whitington PF; Schwimmer JB;
    Clin Gastroenterol Hepatol; 2018 Mar; 16(3):438-446.e1. PubMed ID: 28286193
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ability of Cytokeratin-18 Fragments and FIB-4 Index to Diagnose Overall and Mild Fibrosis Nonalcoholic Steatohepatitis in Japanese Nonalcoholic Fatty Liver Disease Patients.
    Kobayashi N; Kumada T; Toyoda H; Tada T; Ito T; Kage M; Okanoue T; Kudo M
    Dig Dis; 2017; 35(6):521-530. PubMed ID: 29040984
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.